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Submicroscopic, rare chromosomal deletions and duplications
known as copy number variants (CNVs) have been found to
contribute to increased risks of different neurodevelopmental
disorders, notably autism, schizophrenia and intellectual
disability, and most recently attention-deficit hyperactivity dis-
order (ADHD).1–9 However, the types of CNVs most consistently
associated with ADHD and other neurodevelopmental disorders
are individually rare (51% frequency). This raises the question
of whether such mutations are associated with clinically and
developmentally typical disorder. We have previously found that
large, rare CNVs are significantly more common in children with
ADHD than those without ADHD.9 In the present paper, based on
an extension of our previously reported sample, we address a
different question. Specifically, we set out to identify whether
ADHD accompanied by the presence of at least one large, rare
CNV is associated with distinctive clinical, cognitive and
developmental features, differential family loading of psychiatric
disorder and specific pre-/perinatal markers.
Method
Sample
Our sample consisted of 567 children aged 5–17 years
(mean = 10.6, s.d. = 2.82) with a DSM-IV10 or DSM-III-R11
diagnosis of ADHD or ICD-1012 diagnosis of hyperkinetic
disorder. Participants were referred to the study by clinicians from
child and adolescent psychiatry or paediatric out-patient clinics
across the UK. All were of White British origin. Children with
schizophrenia, known autism-spectrum disorder, bipolar disorder,
Tourette syndrome, epilepsy, brain damage or any other known
neurological or genetic disorder were excluded from the study
prior to analysis (n= 18). All children were also screened for
autism-spectrum disorder using the Autism Screening
Questionnaire (ASQ).13 All those who scored above the cut-off
point on the ASQ were reassessed using the same items and
reviewed by a clinical child and adolescent psychiatrist. Those
who still showed high scores or were judged by a clinician to have
possible autism-spectrum disorder were excluded.
This sample is an extension of the 366 children included in a
previous genome-wide study of CNV in ADHD.9 As such, all
methods are identical to those previously described. Ethical
approval for the study was obtained from the North West England
and Wales Multicentre Research Ethics Committees. Written
informed consent from parents and assent from children (and
consent for those aged 16 years and older) were obtained for all
individuals.
Measures
Clinical
Attention-deficit hyperactivity disorder symptoms and diagnoses
in the child were confirmed using the Child and Adolescent
Psychiatry Assessment (CAPA),14 a research diagnostic interview
undertaken with the parent. The presence of impairment and
onset of symptoms/impairment before the age of 7 years that
are needed to confirm diagnoses were also assessed using the
CAPA. All interviewers were trained to a high level of reliability
(kappa = 1.00 for agreement on ADHD diagnosis). Information
on the pervasiveness of ADHD symptoms and impairment in a
school setting was obtained using the Child ADHD Teacher
Telephone Interview (CHATTI)15 or the Conners Teacher Rating
Scale.16
The CAPA14 was also used to assess current symptoms and
diagnoses of comorbid oppositional defiant disorder, conduct
disorder, anxiety disorders (generalised anxiety, social anxiety,
separation anxiety), depression, mania and tic disorders.
Symptoms of these comorbid conditions were also assessed using
the child version of the CAPA17 for children aged 12 years and
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Background
Submicroscopic, rare chromosomal copy number variants
(CNVs) contribute to neurodevelopmental disorders but it is
not known whether they define atypical clinical cases.
Aims
To identify whether large, rare CNVs in attention-deficit
hyperactivity disorder (ADHD) are confined to a distinct
clinical subgroup.
Method
A total of 567 children with ADHD aged 5–17 years were
recruited from community clinics. Psychopathology was
assessed using the Child and Adolescent Psychiatric
Assessment. Large, rare CNVs (4500 kb, 51% frequency)
were defined from single nucleotide polymorphism data.
Results
Copy number variant carriers (13.6%) showed no differences
from non-carriers in ADHD symptom severity, symptom type,
comorbidity, developmental features, family history or pre-/
perinatal markers. The only significant difference was a
higher rate of intellectual disability (24% v. 9%, w2 = 15.5,
P=0.001). Most CNV carriers did not have intellectual
disability.
Conclusions
Large, rare CNVs are not restricted to an atypical form
of ADHD but may be more highly enriched in children with
cognitive problems.
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over. Comorbid symptoms were endorsed if reported by either
parent or child.17 DSM-IV diagnoses and total current symptom
counts for all of the assessed disorders were generated from the
CAPA. Total scores from the ASQ were also computed.
Cognitive measures
Cognitive ability was assessed using the Wechsler Intelligence Scale
for Children,18,19 which obtains an estimate of full scale IQ. For
those aged under 12 years, reading ability was measured using
the Wechsler Objective Reading Dimensions (WORD) assessment
package.20
Pre- and perinatal factors and early development
Data on pre- and perinatal factors were obtained using a well-
validated parent-rated retrospective questionnaire,21 supplemented
with additional questions that have been included in previous
investigations.22–24 We focused on factors previously found to be
associated with ADHD or other neurodevelopmental problems.
Parents reported whether the child had spent any time in a special
care baby unit, the child’s birth weight and the mother’s and
father’s age at the birth of the child. The presence of smoking
during pregnancy (yes/no) was assessed using the question ‘Did
you smoke at all during your pregnancy?’ Parents were also asked
to report on the child’s early development25 using measures found
to discriminate those with ADHD from those without.
Specifically, parents were asked about a delay in speech (not
talking by age 2 years), as well as a delay in walking (not walking
by age 18 months). Parents were also asked whether their child
had suffered from any serious medical conditions. Medical
conditions reported by the parent were coded as congenital in
origin by two independent physicians (e.g. cardiac murmur coded
as congenital, but not asthma).
Family factors
Parents reported on the family’s total annual income and their
educational attainment. Low income was defined as annual
income 5£20 000 and low level of education if one or both
parents had left school without qualifications (GCSEs or O-levels
at 16 years).
Family history was assessed by asking parents to report on the
presence of any mental health problem (ADHD, depression,
anxiety, schizophrenia, mania/bipolar disorder and autism) for
all first-degree relatives of the index child. This information was
used to define the presence of psychiatric disorder in any first-
degree relative. Mothers and fathers (where available) also
provided data on their own current (in the past 6 months) and
childhood ADHD symptoms.10,26 Symptoms that were present
at both time points (childhood onset symptoms that continued
until adult life) were summed to give a total number of maternal
and paternal ADHD symptoms27 and these scores were adjusted
for parental age using linear regression analysis.
CNV identification
The ADHD sample used in this study is an extension of the
n=366 previously analysed for large, rare CNVs and therefore all
quality control and CNV detection protocols were identical to those
previously described.9 Briefly, single nucleotide polymorphisms
were genotyped using the Human660W-Quad BeadChip (Illumina,
San Diego, California, USA) and BeadStudio was used to call
genotypes, normalise the signal intensity data and determine the
log R ratio and B allele frequency at each single nucleotide
polymorphism according to the standard Illumina protocols.
Copy number variants were defined by PennCNV 25 with loci
spanning at least 15 consecutive informative single nucleotide
polymorphisms, those having copy number calls 52 and 42
being classed as deletions and duplications respectively. All
samples with a single nucleotide polymorphism call rate 50.95,
a high standard deviation in their genome-wide log R ratio
(40.30), carrying more than 30 apparent CNVs over 100 kb or
any duplicate or related samples (identity by descent 40.3) were
excluded prior to analysis (n=40). Finally, the application of a
number of CNV validation and quality control procedures (full
details previously published)9 allowed the definition of the set
of large (classified as those 4500 kb), rare (51% frequency)
CNVs that were used in this analysis.
Statistical analyses
The ADHD sample was divided into those with (n=77) and
without (n=490) at least one large, rare CNV, greater than
500 kb in size. The two groups were compared on each of the
clinical, cognitive, pre- and perinatal, developmental and family
factors. All analyses are presented for raw scores/data for ease of
interpretation. To avoid unnecessary multiple testing, the primary
analyses were based on quantitative measures where possible and
categorical definitions of the same constructs were subsequently
tested only if initial association had been found. Where a
variable was not normally distributed, the scores were natural
logarithmically transformed (ln x) and analyses were run on
transformed scores. Continuous measures were compared across
groups using t-tests and categorical variables were examined using
Pearson chi-squared tests.
As ADHD (like autism and schizophrenia) is associated
with lower IQ and its prevalence is higher in individuals with
intellectual disability (full-scale IQ 570),29 we did not exclude
children with intellectual disability from this study. Results are,
however, separately presented for individuals without intellectual
disability (n= 473, of whom 54 have large, rare CNVs) as well
as for the full sample. IQ test scores were not available for 42
children. All analyses were undertaken using SPSS, version 16
for Windows. To take into account multiple testing, using
Bonferroni correction for the number of variables tested, alpha
was set at P=0.002 (0.05/27).
Results
Sample description
Of the total sample of 567 children, 492 (86.8%) were boys. At the
time of assessment, 71.3% (n=404) currently met criteria for
DSM-IV ADHD combined type, 8.3% (n= 48) for inattentive
type, 11.8% (n=67) for hyperactive-impulsive type and 92.9%
(n=527) for current DSM-III-R ADHD. The rates of comorbid
disorder were 43% (n=244) for current DSM-IV oppositional
defiant disorder, 15% (n=85) for conduct disorder, 5.1%
(n=29) for any anxiety disorder and 0.7% (n=4) for any
depressive disorder. Of the total sample, 52 were defined as having
intellectual disability (IQ 570), and 473 had IQ test scores of 70
or above (42 had scores missing for the Weschler Intelligence Scale
for Children).18,19 Overall, 490 (86.4%) children had no large, rare
CNV, 69 (12.2%) had one CNV and 8 (1.4%) had two CNVs (see
online Table DS1 for a full list of CNVs). The proportion of
CNV carriers was similar in this extended sample (13.6%) to
our previously reported rate (14% cases v. 7% controls).9
Clinical and cognitive characteristics
of children with and without large, rare CNVs
Table 1 shows the clinical and cognitive characteristics of children
with and without CNVs. As age and gender were not associated
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with CNV presence, these variables were not included as
covariates in subsequent analyses. As previously observed,9 CNVs
were significantly more common in children with intellectual
disability (IQ 570) but were not restricted to this group. The
majority of CNV carriers in our sample (n= 54, 70.1%) were still
in the group of children without intellectual disability. There were
associations with lower IQ and reading ability test scores but these
did not reach statistical significance following Bonferroni
correction. The IQ distributions in the total sample of children
with ADHD and the subgroup of CNV carriers are shown in
Figs 1 and 2. There were no other clinical phenotypic differences
in children with and without CNVs.
When children with intellectual disability were excluded, CNV
carriers were still not distinguishable on any clinical characteristic,
although CNV carriers showed lower reading ability but not lower
IQ scores. The number of children with CNVs in loci previously
implicated in autism and schizophrenia was small (n=20) and
thus results need to be interpreted with caution. When this group
(without intellectual disability) was clinically compared with non-
CNV carriers, the pattern of results was similar. No significant
differences (after correction for multiple testing) were detected,
although CNV carriers showed lower reading ability and,
interestingly, ASQ scores (none had autism) were higher (online
Table DS2).
Pre-/perinatal, developmental and family factors
Table 2 shows that children with CNVs could not be distinguished
on any pre-or perinatal factor, by an atypical early developmental
history or by familial loading for psychiatric disorder.
Discussion
Children with ADHD who carry large, rare CNVs were found to be
indistinguishable from childrenwithout CNVs in terms of the pattern
and severity of ADHD symptoms and psychiatric comorbidity. Nor
were there any pre-/perinatal, developmental or familial markers
of large, rare CNVs. This suggests that large, rare CNVs do not
appear to be associated with an atypical form of disorder.
The IQ scores for this sample were normally distributed and, in
keeping with previous studies of ADHD,30,31 the IQ distribution
was comparable to the normal population but with a lower mean.
Carriers of large, rare CNVs had a significantly higher rate of
intellectual disability (as previously reported in a subsample of
the present study) and there were associations with lower IQ
scores and reading ability, although the latter did not survive
correction for multiple testing. However, there was no relationship
between possession of CNVs and IQ in those without intellectual
disability. The higher rate of CNVs in children with ADHD and
intellectual disability might be explained by several factors. First,
as shared genetic and familial risk factors contribute to the
association between ADHD and lower IQ in the general
population,31,32 CNVs might have a common risk effect on these
two different but related neurodevelopmental problems. Given
that we have previously observed an overlap of CNVs found in
ADHD with those found in schizophrenia and autism,9 the
hypothesis that CNVs influence multiple neurodevelopmental
phenotype outcomes is plausible.33 A second possibility is that
CNVs might be increasing ADHD risk through effects on
cognition and learning.33 This would explain our observed
association between CNVs, intellectual disability and reading
problems. However, the lack of association between the presence
of CNVs and IQ in children without intellectual disability is
inconsistent with this view. Overall, regardless of explanation,
the results suggest that large, rare CNVs in ADHD, although more
common in individuals with intellectual disability, are not
confined to this group and are relevant across the IQ spectrum.
Nevertheless, given the high rate of large, rare CNVs in children
with intellectual disability, as we have previously highlighted,9 this
group of children (with both ADHD and intellectual disability)
might benefit from a clinical genetics opinion.
As already highlighted, structural variants including large, rare
CNVs are increasingly being considered to contribute to the risk
of ADHD, autism and schizophrenia.1–9 It had been well
recognised, prior to the recent CNV studies, that there are specific
‘syndromic’ types of ADHD, autism and schizophrenia that
appear to be caused by structural chromosomal abnormalities.
For example, chromosome 22q11 microdeletion syndrome
(velocardiofacial syndrome) is associated with increased risks of
ADHD and schizophrenia.34 There is some work, however, to
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Fig. 2 Distribution of IQ scores of all the children with copy
number variants.
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suggest that the pattern of clinical features of ADHD might be
different in this group from those with ‘idiopathic ADHD’. One
study found that children with ADHD and velocardiofacial
syndrome, when compared with idiopathic ADHD, showed higher
rates of ADHD inattentive type and comorbidity.35 In terms of
symptom presentation, we found that children with ADHD who
possess large, rare CNVs when ascertained from non-specialist
clinics were clinically indistinguishable from those who do not
show such mutations. However, the mean level of inattention
symptoms was higher in the CNV carriers and it is possible that
our sample size was not large enough to detect a significant
difference. They also did not differ in terms of familial loading
for ADHD and other psychiatric disorders. These results are in
keeping with the view that these individuals do not have atypical,
rare, syndromic forms of ADHD.
There are only a few studies investigating the phenotypic
manifestations of CNVs in other disorders. One study was based
on 100 individuals with autism-spectrum disorder.36 The sample
was ascertained for developmental complexity and CNVs were
rated as present if considered pathogenic (de novo or absent in
controls) but psychiatric phenotype data were not available. Those
with pathogenic CNVs were most strongly distinguished by a
higher rate of intellectual disability but not by pre-/perinatal
factors. Other studies of autism-spectrum disorder have been
mixed.37 Interestingly, some studies have found associations
between specific CNVs and larger and smaller head sizes in
intellectual disability and schizophrenia.38 We did not have
measures of head circumference. Others have also suggested
that higher paternal age is associated with autism39 and
schizophrenia,40 but not ADHD,41 and it is this that might result
in increased rates of mutations in sperm and offspring genomic
alterations.42 In our study, there was no relationship between
those carrying a CNV and older parental age.
Although our sample is the largest CNV study of ADHD
published to date, there are a number of limitations. First, the
sample size may have been too small to distinguish phenotypic
differences of small effect size. Second, we did not have data on
whether the CNVs in this full sample were de novo or inherited
to test these separately. A challenge to examining parent of origin
effects in ADHD in UK community clinic samples is that many
fathers are not available. We also had no formal assessments of
dysmorphic features or detailed assessments of subtle congenital
anomalies. Another issue is that in most CNV studies, including
our own, large, rare CNVs are located at different chromosomal
loci and it is likely that all CNVs are not equally predisposing.
Finally, although an increased burden of CNVs has been reported
in ADHD and other neurodevelopmental disorders, it is difficult
to assess whether they play a causal role. We cannot determine
that by observing association alone.
In summary, rare structural variants have increasingly
been implicated as contributing to ADHD and other neuro-
developmental disorders. However, it is not known whether the
form of ADHD that occurs in carriers of large, rare CNVs is
typical of the disorder as a whole. Our results suggest that, apart
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Table 1 Clinical and cognitive characteristics of children with and without copy number variants (CNVs)
Full sample (including those with intellectual disability) Children with IQ570
CNVs No CNVs CNVs No CNVs
Variable N Mean (s.d.) n (%) Mean (s.d.) n (%) t/w2 P N Mean (s.d.) n (%) Mean (s.d.) n (%) t/w2 P
Child’s gender,
% male 567 66 (85.7) 426 (86.9) 0.09 0.77 473 49 (90.7) 362 (86.4) 0.79 0.37
Child’s age, years 567 10.4 (2.8) 10.7 (2.8) 0.61 0.55 473 10.1 (2.6) 10.5 (2.7) 1.13 0.26
ADHD symptoms
(max. 18) 546 15.1 (2.4) 14.8 (2.8) 70.95 0.56a 454 15.1 (2.5) 14.8 (2.9) 70.58 0.78a
Inattention
symptoms
(max. 9) 554 7.6 (1.4) 7.2 (1.8) 71.99 0.10a 462 7.8 (1.2) 7.2 (1.8) 72.29 0.04a
Hyperactivity
symptoms
(max. 5) 560 4.2 (1.1) 4.3 (1.1) 0.62 0.43a 466 4.1 (1.2) 4.3 (1.1) 1.56 0.10a
Impulsive
symptoms
(max. 4) 560 3.3 (0.9) 3.2 (0.9) 70.27 0.80a 466 3.2 (0.9) 3.3 (0.9) 0.39 0.61a
CD symptoms
(max. 14) 544 1.4 (1.7) 1.2 (1.3) 0.99 0.78a 459 1.3 (1.6) 1.2 (1.3) 0.46 0.90a
Anxiety
symptoms
(max. 12) 417 1.2 (1.8) 1.0 (1.3) 0.87 0.56a 335 1.2 (1.7) 0.9 (1.3) 1.12 0.32a
Depression
symptoms
(max. 9) 537 1.2 (1.3) 1.1 (1.2) 0.69 0.53a 451 1.2 (1.3) 1.0 (1.0) 1.30 0.25a
ASQ score 341 12.6 (6.4) 12.6 (6.7) 70.01 0.99 281 11.7 (6.1) 12.1 (6.2) 0.36 0.72
Intellectual
disability,
presenceb 529 17 (23.9) 39 (8.5) 15.46 0.0001
Full-scale IQ score 525 81.4 (13.3) 85.4 (13.3) 2.33 0.02 473 86.3 (9.7) 87.7 (11) 0.90 0.37
WORD composite
score 273 78.3 (14.7) 84.6 (15.1) 2.44 0.02 257 79.3 (15.3) 85.6 (14.5) 2.33 0.02
ADHD, attention-deficit hyperactivity disorder; ASQ, Autism Screening Questionnaire; CD, conduct disorder; max., maximum; WORD, Wechsler Objective Reading Dimensions scale.
a. Analysis on transformed data.
b. Four individuals known to have intellectual disability based on testing by the clinic (e.g. British Ability Scale) but with no study IQ test scores available.
Langley et al
from an increased risk of CNVs in children with comorbid
intellectual disability, large, rare CNVs do not appear to be
restricted to an atypical subgroup of children with ADHD. These
findings have implications for selecting populations for CNV
screening and suggest that other classes of rare mutations might
also be found in typical clinical cases.
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Data supplement
Table DS1 List of large, rare copy number variant (CNV) locations and types for all cases
Child with
intellectual disability Location of CNV Type of CNV Location of 2nd CNV Type of 2nd CNV
Yes 2q11.2 Duplication
Yes 3p26.3 Duplication
Yes 3q29 Duplication
Yes 4q13.1 Duplication
Yes 4q32.2 Deletion 6q22.33-q23.1 Duplication
Yes 6q22.31 Duplication
Yes 6q24.1 Duplication
Yes 8p12 Duplication 22q11.21-q11.22 Duplication
Yes 8p23.2-p23.1 Deletion
Yes 10q11.22-q11.23 Deletion
Yes 11p11.12 Duplication
Yes 12p11.1 Duplication
Yes 14q21.1 Deletion
Yes 15q12-q13.1 Duplication
Yes 15q13.1-q13.2 Duplication
Yes 16p11.2 Deletion
Yes 20p13 Deletion
No 1p32.3 Duplication
No 1q23.2 Deletion
No 1q44 Deletion 11p15.4 Deletion
No 2p22.3 Duplication
No 2q23.3 Duplication
No 3p22.3 Duplication
No 3p26.1 Duplication
No 3p26.2-p26.1 Deletion
No 3p26.3 Duplication
No 3p26.3 Duplication
No 3q11.2 Duplication
No 3q29 Duplication
No 4p15.2 Duplication
No 4p15.2 Duplication
No 4p15.31 Duplication
No 4q13.1 Deletion 4q22.1 Duplication
No 4q13.3 Duplication
No 4q13.3-q21.1 Duplication
No 4q35.1 Duplication
No 6q24.1 Duplication
No 7p21.1 Duplication 16p13.11 Duplication
No 7q11.22 Duplication
No 7q31.32 Duplication
No 8q21.2-q21.3 Deletion 17q12 Duplication
No 8q21.3 Duplication
No 10q11.22-q11.23 Deletion
No 11q13.2-q13.3 Duplication
No 11q22.2-q22.3 Deletion
No 11q25 Duplication
No 12p11.1 Duplication
No 13q21.31 Deletion 20p12.1 Duplication
No 15q11.2-q12 Duplication
No 15q12-q13.1 Duplication
No 15q13.1-q13.2 Duplication
No 15q13.1-q13.2 Duplication
No 15q13.1-q13.2 Duplication
No 15q13.1-q13.2 Duplication
No 15q13.1-q13.2 Duplication
No 15q13.1-q13.2 Duplication
No 15q13.2-q13.3 Deletion
No 15q13.2-q13.3 Duplication
No 16p11.2 Deletion
(continued)
2Table DS1 List of large, rare copy number variant (CNV) locations and types for all cases (continued)
Child with
intellectual disability Location of CNV Type of CNV Location of 2nd CNV Type of 2nd CNV
No 16p12.2 Deletion
No 16p13.11 Duplication
No 16p13.11 Duplication
No 16p13.11 Duplication
No 16p13.11 Duplication
No 16p13.11 Duplication
No 16p13.11-p12.3 Duplication
No 16p13.11-p12.3 Duplication
No 17q12 Deletion
No 17q12 Duplication
No 19q13.11 Deletion
No 22q11.1-q11.21 Duplication
Unknown 1q42.3-q43 Duplication
Unknown 2p22.3 Duplication
Unknown 3q26.1 Deletion 16p11.2 Duplication
Unknown 3q26.31 Duplication
Unknown 8p23.1 Duplication
Unknown 15q13.1-q13.2 Duplication
Table DS2 Clinical and cognitive characteristics of children with and without copy number variants (CNVs) implicated in
schizophrenia and autism
Children with IQ570
CNVs No CNVs
Variable n Mean (s.d.) n (%) Mean (s.d.) n (%) t/w2 P
Child’s gender, % male 439 18(90) 362(86.4) 0.21 0.64
Child’s age, years 439 10.2 (2.7) 10.5 (2.7) 0.62 0.54
ADHD symptoms (max. 18) 421 14.9 (2.7) 14.8 (2.9) 70.11 1.00a
Inattention symptoms (max. 9) 429 7.9 (1.2) 7.2 (1.8) 71.62 0.12a
Hyperactivity symptoms (max. 5) 432 3.9 (1.4) 4.3 (1.1) 1.69 0.13a
Impulsive symptoms (max. 4) 432 3.2 (1.1) 3.3 (0.9) 0.49 0.78a
CD symptoms (max. 14) 426 1.4 (1.5) 1.3 (1.6) 70.35 0.54a
Anxiety symptoms (max. 12) 310 1.3 (1.1) 1.2 (1.7) 70.06 0.58a
Depression symptoms (max. 9) 418 0.9 (0.8) 1.2 (1.3) 1.22 0.34a
ASQ score 258 14.9 (6.6) 12.1 (6.2) 71.51 0.13
Full-scale IQ score 439 84.6 (10.8) 87.7 (11) 1.25 0.21
WORD composite score 237 75.9 (15.6) 85.6 (14.5) 2.41 0.02
ADHD, attention-deficit hyperactivity disorder; ASQ, Autism Screening Questionnaire; CD, conduct disorder; max., maximum; WORD, Wechsler Objective Reading Dimensions scale.
a. Analysis on transformed data.
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